Lead Product(s) : Esonadogene Imvoparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Yangtze River-CMB International Industry Fund
Deal Size : $95.0 million
Deal Type : Series C Financing
Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials
Details : The net proceeds will advance clinical trials for Neurophth's core products, enhancing the firm's R&D capabilities and expanding its pipeline, including NFS-01 (esonadogene imvoparvovec), a rAAV2-ND4 gene therapy being developed to treat Leber's heredita...
Product Name : Opvika
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 08, 2023
Lead Product(s) : Esonadogene Imvoparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Yangtze River-CMB International Industry Fund
Deal Size : $95.0 million
Deal Type : Series C Financing
Lead Product(s) : rAAV2-ND4
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON
Details : NR082 (rAAV2-ND4), a recombinant adeno-associated viral vector, serotype 2, containing human ND4 codon-optimized gene under the control of the cytomegalovirus promoter and enhancer, is a novel gene therapy.
Product Name : NR082
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 15, 2022
Lead Product(s) : rAAV2-ND4
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : rAAV2-ND4
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings
Details : Results of two clinical studies utilizing NFS-01 in the treatment of Leber's Hereditary Optic Neuropathy will be presented in May 2020 at the ASGCT Annual Meeting.
Product Name : NR082
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : rAAV2-ND4
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : rAAV2-ND4
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NR082 is the first candidate drug developed by Neurophth. It uses recombinant adeno-associated virus serotype 2 to deliver the genetically modified ND4 gene (rAAV2-ND4).
Product Name : NR082
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : rAAV2-ND4
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable